Dr. Fazal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4815 Liberty Ave
Ste 322
Pittsburgh, PA 15224Phone+1 412-578-4484Fax+1 412-578-3536
Summary
- Dr. Salman Fazal, based in Pittsburgh, PA, specializes in hematology with a subspecialty in hematologic oncology. He completed his medical training at King Edward Medical University followed by a residency in internal medicine and a fellowship in hematology and medical oncology. Dr. Fazal serves as the Director of the Cell Transplantation Program at Allegheny Health Network Cancer Institute and holds additional leadership roles at West Penn Hospital and Western Pennsylvania Allegheny Health System. He is also an Assistant Professor at the Lewis Katz School of Medicine at Temple University. He has extensive experience in hematologic oncology, specifically in conditions such as Hodgkin's lymphoma and myelodysplastic syndromes. His numerous publications include research on antiviral treatments post-stem cell transplantation and novel therapies for hematologic diseases.
Education & Training
- Allegheny Health Network Medical Education Consortium (WPH/AGH)Fellowship, Hematology and Medical Oncology, 2007 - 2010
- Chicago Medical School/Rosalind Franklin University of Medicine & ScienceResidency, Internal Medicine, 2003 - 2006
- King Edward Medical UniversityClass of 2001
Certifications & Licensure
- PA State Medical License 2007 - 2026
- CT State Medical License 2006 - 2007
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML.Guillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, Karen W L Yee, Amer M Zeidan
Future Oncology. 2025-04-01 - Low-Dose Acyclovir Reduces the Reactivation of Herpes Simplex and Varicella Zoster Viruses After Allogeneic Stem Cell Transplantation.Sorana G Ursu, Mohammad M Alhousani, Gina Patrus, Salman Fazal
Cureus. 2024-12-01 - 6 citationsSafety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial.Vikas Gupta, Abdulraheem Yacoub, Ruben A Mesa, Claire N Harrison, Alessandro M Vannucchi
Leukemia & Lymphoma. 2024-09-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: